董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 黄岚 | 女 | Co-Founder, Chairperson and Chief Executive Officer | 54 | 79.34万美元 | 675.46 | 2025-03-27 |
| Patrick Fabbio | 男 | Director | 57 | 6.34万美元 | 10.96 | 2025-03-27 |
| Matthew Kirkby | 男 | Director | 56 | 7.14万美元 | 10.49 | 2025-03-27 |
| Sihai Xu | 男 | Director | 53 | 4.74万美元 | 5.14 | 2025-03-27 |
| Jiangwen Majeti | 女 | Director | 57 | 6.14万美元 | 10.66 | 2025-03-27 |
| Brendan Delaney | 男 | Director | 50 | 5.54万美元 | 9.99 | 2025-03-27 |
高管介绍
注：高管持股数取自最新公司公告
董事简历
中英对照 | 中文 | 英文- 黄岚
-
黄岚博士在中国和美国的生物技术产业拥有十多年的创业经验。她发明并拥有多项生物技术产品专利，用于肿瘤和皮肤病适应症。2009年，她成为“国家千人计划”的获得者之一。在2013年创立BeyondSpring之前，黄岚博士共同创办了无锡麦涛岚华生物科技有限公司，并于2010年将其自主设计的多肽药物的中国权利卖给中国制药公司排名前三的上药集团。在中国她还共同创立了一个临床CRO公司Paramax，之后出售给RPS （一个全球性CRO），后者在2011年以超过2亿美元将之出售给Warburg Pincus。此外，黄博士还是Forward Venture公司的合伙人，负责Forward Venture的投资公司和中国制药公司的合作计划。黄岚博士曾在Memorial Sloan-Kettering癌症中心（MSKCC）学习，其博士学位由加州大学伯克利分校化学系授予，同时也获得了北美优秀女博士毕业奖。她的关于Ras和P53的癌症信号通路的研究发表在Science and Nature杂志上。黄岚博士曾就读于上海复旦大学，且获得了劳伦斯大学的学士学位、优等生和美国大学优生等荣誉，目前她在那里担任董事。
Lan Huang,is co-founder, Chairperson and Chief Executive Officer and has been a member of board of directors since November 2014. Dr. Huang has over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang co-founded Wanchun Biotech, the former holding company of U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd, where she served as Chief Executive Officer in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd, were sold to Shanghai Pharmaceutical Group in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Currently, Dr. Huang serves on the board of directors of Sincere Efforts Foundations Inc., a non-profit organization. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving P53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications. Dr. Huang received her B.A., magna cum laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women's Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China. - 黄岚博士在中国和美国的生物技术产业拥有十多年的创业经验。她发明并拥有多项生物技术产品专利，用于肿瘤和皮肤病适应症。2009年，她成为“国家千人计划”的获得者之一。在2013年创立BeyondSpring之前，黄岚博士共同创办了无锡麦涛岚华生物科技有限公司，并于2010年将其自主设计的多肽药物的中国权利卖给中国制药公司排名前三的上药集团。在中国她还共同创立了一个临床CRO公司Paramax，之后出售给RPS （一个全球性CRO），后者在2011年以超过2亿美元将之出售给Warburg Pincus。此外，黄博士还是Forward Venture公司的合伙人，负责Forward Venture的投资公司和中国制药公司的合作计划。黄岚博士曾在Memorial Sloan-Kettering癌症中心（MSKCC）学习，其博士学位由加州大学伯克利分校化学系授予，同时也获得了北美优秀女博士毕业奖。她的关于Ras和P53的癌症信号通路的研究发表在Science and Nature杂志上。黄岚博士曾就读于上海复旦大学，且获得了劳伦斯大学的学士学位、优等生和美国大学优生等荣誉，目前她在那里担任董事。
- Lan Huang,is co-founder, Chairperson and Chief Executive Officer and has been a member of board of directors since November 2014. Dr. Huang has over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang co-founded Wanchun Biotech, the former holding company of U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd, where she served as Chief Executive Officer in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd, were sold to Shanghai Pharmaceutical Group in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Currently, Dr. Huang serves on the board of directors of Sincere Efforts Foundations Inc., a non-profit organization. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving P53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications. Dr. Huang received her B.A., magna cum laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women's Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.
- Patrick Fabbio
-
Patrick Fabbio于2015年11月加入本公司，担任高级副总裁兼首席财务官。在加入Progenics之前，他是electroCore（一家私人持有的生物电疗医疗公司）的首席财务官，以及NPS Pharmaceuticals, Inc.（一家上市的全球罕见疾病公司）的财务副总裁。 Fabbio先生在公共和私人生命科学和制药公司拥有超过20年的财务领导经验，包括：Catalent Pharma Solutions金融的副总裁；Ikano Therapeutics的首席财务官；Sanofi高级企业融资，商业和交易职位；和Biomatrix Inc.（一家公开上市的生物技术公司，被Genzyme收购）的公司财务主管。他毕业于 Pace University会计学的商学士学位和Stern School of Business at New York University的金融硕士学位。他在新泽西州获得了注册会计师执照。
Patrick Fabbio,has served on board since January 2018. Mr. Fabbio is currently the Chief Financial Officer of Protara Therapeutics, Inc. Mr. Fabbio has more than 30 years of financial, operational and transactional leadership experience in both publicly-traded and privately-held life science and pharmaceutical companies. Prior to joining Protara Therapeutics, Inc., Mr. Fabbio was Chief Financial Officer of Rafael Holdings, Inc. Previously he served as the Chief Financial Officer of WindMIL Therapeutics Inc., Progenics Pharmaceuticals, Inc., electroCore Medical, LLC; Vice President of Finance at NPS Pharmaceuticals, Inc.; Vice President of Finance, Innovation and Growth at Catalent Pharma Solutions Inc.; and Chief Financial Officer at Ikano Therapeutics. His other prior financial positions include roles at Sanofi, UniPath Diagnostics, BioMatrix and Coopers & Lybrand. He received his B.B.A. in accounting at Pace University and MBA from the Stern School of Business at New York University. - Patrick Fabbio于2015年11月加入本公司，担任高级副总裁兼首席财务官。在加入Progenics之前，他是electroCore（一家私人持有的生物电疗医疗公司）的首席财务官，以及NPS Pharmaceuticals, Inc.（一家上市的全球罕见疾病公司）的财务副总裁。 Fabbio先生在公共和私人生命科学和制药公司拥有超过20年的财务领导经验，包括：Catalent Pharma Solutions金融的副总裁；Ikano Therapeutics的首席财务官；Sanofi高级企业融资，商业和交易职位；和Biomatrix Inc.（一家公开上市的生物技术公司，被Genzyme收购）的公司财务主管。他毕业于 Pace University会计学的商学士学位和Stern School of Business at New York University的金融硕士学位。他在新泽西州获得了注册会计师执照。
- Patrick Fabbio,has served on board since January 2018. Mr. Fabbio is currently the Chief Financial Officer of Protara Therapeutics, Inc. Mr. Fabbio has more than 30 years of financial, operational and transactional leadership experience in both publicly-traded and privately-held life science and pharmaceutical companies. Prior to joining Protara Therapeutics, Inc., Mr. Fabbio was Chief Financial Officer of Rafael Holdings, Inc. Previously he served as the Chief Financial Officer of WindMIL Therapeutics Inc., Progenics Pharmaceuticals, Inc., electroCore Medical, LLC; Vice President of Finance at NPS Pharmaceuticals, Inc.; Vice President of Finance, Innovation and Growth at Catalent Pharma Solutions Inc.; and Chief Financial Officer at Ikano Therapeutics. His other prior financial positions include roles at Sanofi, UniPath Diagnostics, BioMatrix and Coopers & Lybrand. He received his B.B.A. in accounting at Pace University and MBA from the Stern School of Business at New York University.
- Matthew Kirkby
-
Matthew Kirkby，他担任任职Beyondspring Inc. 董事会（2016年10月13日以来）。他为Beyondspring Inc. 董事会提供超过20年的银行工作经验。他曾担任伦敦、中国香港和新加坡的高级管理职务。2015年至2016年，他曾担任HSBC（位于中国香港）的企业银行亚太区主管。2012年至2015年，他曾担任CIMB（位于中国香港）的东北亚首席执行官、投资银行联席主管。他曾担任the Royal Bank of Scotland的董事总经理、全球ECM和企业融资主管（2008年至2010年），以及董事总经理、全球银行亚太区的负责人（2010年至2012年）。从1999年到2007年，他曾担任ABN AMRO公司的多种管理职位。他也担任一些民营公司的董事或顾问。他持有牛津大学彭布罗克学院（Pembroke College, University of Oxford，位于英国）的法学硕士学位。
Matthew Kirkby,has served on board since October 2016. Mr. Kirkby has over 20 years of banking experience to Beyondspring Inc. board. He has held senior management positions in London, Hong Kong and Singapore for a number of global banks including HSBC, RBS and ABN AMRO. He is currently a director or board adviser to a number of privately-held companies. He received his M.A. in jurisprudence at Pembroke College, University of Oxford in the United Kingdom. He is currently an Advisory Fellow and member of the Governing Body of Pembroke College. Mr. Kirkby is a qualified solicitor in England and Wales and Hong Kong. - Matthew Kirkby，他担任任职Beyondspring Inc. 董事会（2016年10月13日以来）。他为Beyondspring Inc. 董事会提供超过20年的银行工作经验。他曾担任伦敦、中国香港和新加坡的高级管理职务。2015年至2016年，他曾担任HSBC（位于中国香港）的企业银行亚太区主管。2012年至2015年，他曾担任CIMB（位于中国香港）的东北亚首席执行官、投资银行联席主管。他曾担任the Royal Bank of Scotland的董事总经理、全球ECM和企业融资主管（2008年至2010年），以及董事总经理、全球银行亚太区的负责人（2010年至2012年）。从1999年到2007年，他曾担任ABN AMRO公司的多种管理职位。他也担任一些民营公司的董事或顾问。他持有牛津大学彭布罗克学院（Pembroke College, University of Oxford，位于英国）的法学硕士学位。
- Matthew Kirkby,has served on board since October 2016. Mr. Kirkby has over 20 years of banking experience to Beyondspring Inc. board. He has held senior management positions in London, Hong Kong and Singapore for a number of global banks including HSBC, RBS and ABN AMRO. He is currently a director or board adviser to a number of privately-held companies. He received his M.A. in jurisprudence at Pembroke College, University of Oxford in the United Kingdom. He is currently an Advisory Fellow and member of the Governing Body of Pembroke College. Mr. Kirkby is a qualified solicitor in England and Wales and Hong Kong.
- Sihai Xu
-
Sihai Xu，MBA，自2022年8月起担任Beyondspring Inc.董事会成员。他此前是Beyondspring Inc.的员工，并于2016年11月至2022年1月担任国际业务协调员。他在中国担任财务主管近30年。他最近的职位是BOJI Health Investment Management （Shanghai） Co.， Ltd.的首席财务官和董事会成员（2014年以来）。曾任河南整形外科医院首席财务官、上海博济医院投资管理有限公司首席财务官、河南智毅投资管理有限公司首席财务官、洛阳春都集团财务总监。作为财务顾问和战略投资者，他参与了中国大陆和香港数十家上市公司的IPO前期、IPO和重大资产重组，如河南塔洛药业股份有限公司、河南凌瑞药业股份有限公司、新乡化纤股份有限公司、华中大地传媒股份有限公司和中国钼业股份有限公司。他在中国人民大学获得工商管理硕士学位，在中国河南经济与法律大学获得学士学位，主修财务会计。他在中国公认会计准则方面经验丰富。
Sihai Xu,has served on board since August 2022. Mr. Xu was previously employee and served as International Business Coordinator from November 2016 to January 2022. Mr. Xu has been an accomplished financial executive for almost 30 years in China. His most recent role since 2014 is the CFO and board member of BOJI Health Investment Management (Shanghai) Co., Ltd. Prior engagements include CFO of Henan Plastic Surgery Hospital, CFO of Shanghai BOJI Hospital Investment Management Co., Ltd., CFO of Henan Zhiyi Investment Management Co., Ltd., and Director of Finance of Luoyang Chundu Group. As a financial advisor and strategic investor, Mr. Xu has participated in pre-IPO, IPO, and major asset restructuring for dozens of public companies in China and Hong Kong, such as Henan Taloph Pharmaceutical Stock Co., Ltd., and Henan Lingrui Pharmaceutical Co., Ltd., Xinxiang Chemical Fiber Co. Ltd., Central China Land Media Co. Ltd., and China Molybdenum Co., Ltd. Mr. Xu received his MBA from Renmin University in China and his bachelor's degree from Henan University of Economics and Law in China, with a major in Financial Accounting. He is experienced with China GAAP. - Sihai Xu，MBA，自2022年8月起担任Beyondspring Inc.董事会成员。他此前是Beyondspring Inc.的员工，并于2016年11月至2022年1月担任国际业务协调员。他在中国担任财务主管近30年。他最近的职位是BOJI Health Investment Management （Shanghai） Co.， Ltd.的首席财务官和董事会成员（2014年以来）。曾任河南整形外科医院首席财务官、上海博济医院投资管理有限公司首席财务官、河南智毅投资管理有限公司首席财务官、洛阳春都集团财务总监。作为财务顾问和战略投资者，他参与了中国大陆和香港数十家上市公司的IPO前期、IPO和重大资产重组，如河南塔洛药业股份有限公司、河南凌瑞药业股份有限公司、新乡化纤股份有限公司、华中大地传媒股份有限公司和中国钼业股份有限公司。他在中国人民大学获得工商管理硕士学位，在中国河南经济与法律大学获得学士学位，主修财务会计。他在中国公认会计准则方面经验丰富。
- Sihai Xu,has served on board since August 2022. Mr. Xu was previously employee and served as International Business Coordinator from November 2016 to January 2022. Mr. Xu has been an accomplished financial executive for almost 30 years in China. His most recent role since 2014 is the CFO and board member of BOJI Health Investment Management (Shanghai) Co., Ltd. Prior engagements include CFO of Henan Plastic Surgery Hospital, CFO of Shanghai BOJI Hospital Investment Management Co., Ltd., CFO of Henan Zhiyi Investment Management Co., Ltd., and Director of Finance of Luoyang Chundu Group. As a financial advisor and strategic investor, Mr. Xu has participated in pre-IPO, IPO, and major asset restructuring for dozens of public companies in China and Hong Kong, such as Henan Taloph Pharmaceutical Stock Co., Ltd., and Henan Lingrui Pharmaceutical Co., Ltd., Xinxiang Chemical Fiber Co. Ltd., Central China Land Media Co. Ltd., and China Molybdenum Co., Ltd. Mr. Xu received his MBA from Renmin University in China and his bachelor's degree from Henan University of Economics and Law in China, with a major in Financial Accounting. He is experienced with China GAAP.
- Jiangwen Majeti
-
Jiangwen Majeti，自2022年8月起任职。Majeti博士是一位投资者、生物技术公司顾问和高管，在生物技术和制药行业拥有20多年的经验。她在生物技术和大型跨国公司中担任的角色多种多样，责任越来越大，包括在生物制药行业的研发、业务发展、供应商管理和外包方面的跨职能经验。最近，她担任纳斯达克上市公司Erasca的全球合作主管兼中国区总经理，管理全球合作，并监督CRO以提高生产力并最大限度地降低成本。在此之前，她是罗氏外部联盟的全球Category Leader、BioDuro业务发展高级总监，以及Amgen的高级科学家。Majeti博士是美籍华人生物制药协会的前任主席，该协会是一个拥有3000多名成员的非营利组织，专注于在美国的生物制药专业人士中建立一个更强大的社区。她还是BayHelix集团的成员，这是一个由商业领袖组成的非营利性专业组织，其使命是在全球范围内塑造生命科学和医疗保健行业的增长，在中国和美国拥有强大的影响力。Majeti博士在威斯康星大学麦迪逊分校获得分子遗传学博士学位，并在加州大学旧金山分校霍华德休斯医学研究所获得博士后培训。她还获得了圣克拉拉大学利维商学院的MBA学位，毕业后成为Beta Gamma Sigma荣誉协会的成员。她在中国复旦大学完成了生物化学的本科学习。
Jiangwen Majeti,has served on board since August 2022. Dr. Majeti is an investor, biotech company advisor, and executive with more than 20 years of experience in the biotech and pharmaceutical industry. She carried out diverse roles with increasing responsibilities in both biotech and large multinational companies, encompassing cross-functional experiences in R&D, business development, supplier management, and outsourcing in the biopharmaceutical industry. Most recently, she was the Head of Global Collaborations and General Manager, China of Erasca, a NASDAQ traded company, managing global collaboration, and overseeing CROs to increase productivity and minimize costs. Prior to that, she was Global Category Leader for Roche External Alliance, Senior Director of Business Development for BioDuro, and Senior Scientist at Amgen. Dr. Majeti is the past president of the Chinese-American Biopharmaceutical Society, a non-profit organization with more than 3,000 members focused on building a stronger community among biopharmaceutical professionals in the U.S. She is also a member of the BayHelix Group, a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry globally with a strong presence in China and the U.S. Dr. Majeti received her Ph.D. in molecular genetics from the University of Wisconsin at Madison, and obtained her postdoctoral training at the Howard Hughes Medical Institute of the University of California, San Francisco. She also earned an MBA from the Leavey School of Business at Santa Clara University, graduating as a member of the Beta Gamma Sigma Honor Society. She completed her undergraduate studies in biochemistry at Fudan University in China. - Jiangwen Majeti，自2022年8月起任职。Majeti博士是一位投资者、生物技术公司顾问和高管，在生物技术和制药行业拥有20多年的经验。她在生物技术和大型跨国公司中担任的角色多种多样，责任越来越大，包括在生物制药行业的研发、业务发展、供应商管理和外包方面的跨职能经验。最近，她担任纳斯达克上市公司Erasca的全球合作主管兼中国区总经理，管理全球合作，并监督CRO以提高生产力并最大限度地降低成本。在此之前，她是罗氏外部联盟的全球Category Leader、BioDuro业务发展高级总监，以及Amgen的高级科学家。Majeti博士是美籍华人生物制药协会的前任主席，该协会是一个拥有3000多名成员的非营利组织，专注于在美国的生物制药专业人士中建立一个更强大的社区。她还是BayHelix集团的成员，这是一个由商业领袖组成的非营利性专业组织，其使命是在全球范围内塑造生命科学和医疗保健行业的增长，在中国和美国拥有强大的影响力。Majeti博士在威斯康星大学麦迪逊分校获得分子遗传学博士学位，并在加州大学旧金山分校霍华德休斯医学研究所获得博士后培训。她还获得了圣克拉拉大学利维商学院的MBA学位，毕业后成为Beta Gamma Sigma荣誉协会的成员。她在中国复旦大学完成了生物化学的本科学习。
- Jiangwen Majeti,has served on board since August 2022. Dr. Majeti is an investor, biotech company advisor, and executive with more than 20 years of experience in the biotech and pharmaceutical industry. She carried out diverse roles with increasing responsibilities in both biotech and large multinational companies, encompassing cross-functional experiences in R&D, business development, supplier management, and outsourcing in the biopharmaceutical industry. Most recently, she was the Head of Global Collaborations and General Manager, China of Erasca, a NASDAQ traded company, managing global collaboration, and overseeing CROs to increase productivity and minimize costs. Prior to that, she was Global Category Leader for Roche External Alliance, Senior Director of Business Development for BioDuro, and Senior Scientist at Amgen. Dr. Majeti is the past president of the Chinese-American Biopharmaceutical Society, a non-profit organization with more than 3,000 members focused on building a stronger community among biopharmaceutical professionals in the U.S. She is also a member of the BayHelix Group, a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry globally with a strong presence in China and the U.S. Dr. Majeti received her Ph.D. in molecular genetics from the University of Wisconsin at Madison, and obtained her postdoctoral training at the Howard Hughes Medical Institute of the University of California, San Francisco. She also earned an MBA from the Leavey School of Business at Santa Clara University, graduating as a member of the Beta Gamma Sigma Honor Society. She completed her undergraduate studies in biochemistry at Fudan University in China.
- Brendan Delaney
-
Brendan Delaney从2021年1月开始担任Constellation Pharma的首席商务官。Constellation最近被Morphosys以14亿美元收购。在加入Constellation之前，Delaney先生是Immunomedics的首席商务官，在那里他领导了营销、销售、市场准入和商业运营团队的建设。他在成功推出Trodelvy方面发挥了重要作用，Trodelvy是首个治疗三阴性乳腺癌的Trop-2导向抗体药物偶联物。Immunomedics于2020年9月被吉利德科学（Gilead Sciences）以210亿美元收购。此前，他曾担任Celgene Corporation美国血液学-肿瘤学副总裁。加入Celgene之前，他曾在Novartis Oncology和Genentech担任多个商业职位，领导Blockbuster Brands的多个成功产品发布。他在纽约大学斯特恩商学院（Stern School of Business）获得MBA学位，在罗格斯大学（Rutgers University）获得生物学学士学位。
Brendan Delaney,has served on board since July 2021. Mr. Delaney has more than 25 years of global product strategy and launch experience to his role leading commercial organizations. He currently serves as an independent consultant to emerging biotech companies. He was previously the Chief Operating Officer and Chief Executive Officer of Aadi Bioscience. Prior to joining Aadi Bioscience, he served as the Chief Commercial Officer of Constellation Pharmaceuticals before it was acquired by MorphoSys for $1.4B in June 2021. Prior to joining Constellation, Mr. Delaney was the Chief Commercial Officer at Immunomedics, where he led the buildout of the marketing, sales, market access and commercial operations teams. He was instrumental in successfully launching Trodelvy, the first TROP-2 directed antibody-drug conjugate for the treatment of triple-negative breast cancer. Immunomedics was acquired by Gilead Sciences for $21B in September 2020. Previously, he served as Vice President of U.S. Hematology-Oncology at Celgene Corporation. Prior to joining Celgene, he held various commercial roles at both Novartis Oncology and Genentech, where he led several successful product launches for blockbuster brands. Mr. Delaney also serves on the Board of Directors of MJH Life Sciences, one of the leading medical-media companies in the United States. He received an MBA from the Stern School of Business at the New York University and a B.A. in biology from Rutgers University. - Brendan Delaney从2021年1月开始担任Constellation Pharma的首席商务官。Constellation最近被Morphosys以14亿美元收购。在加入Constellation之前，Delaney先生是Immunomedics的首席商务官，在那里他领导了营销、销售、市场准入和商业运营团队的建设。他在成功推出Trodelvy方面发挥了重要作用，Trodelvy是首个治疗三阴性乳腺癌的Trop-2导向抗体药物偶联物。Immunomedics于2020年9月被吉利德科学（Gilead Sciences）以210亿美元收购。此前，他曾担任Celgene Corporation美国血液学-肿瘤学副总裁。加入Celgene之前，他曾在Novartis Oncology和Genentech担任多个商业职位，领导Blockbuster Brands的多个成功产品发布。他在纽约大学斯特恩商学院（Stern School of Business）获得MBA学位，在罗格斯大学（Rutgers University）获得生物学学士学位。
- Brendan Delaney,has served on board since July 2021. Mr. Delaney has more than 25 years of global product strategy and launch experience to his role leading commercial organizations. He currently serves as an independent consultant to emerging biotech companies. He was previously the Chief Operating Officer and Chief Executive Officer of Aadi Bioscience. Prior to joining Aadi Bioscience, he served as the Chief Commercial Officer of Constellation Pharmaceuticals before it was acquired by MorphoSys for $1.4B in June 2021. Prior to joining Constellation, Mr. Delaney was the Chief Commercial Officer at Immunomedics, where he led the buildout of the marketing, sales, market access and commercial operations teams. He was instrumental in successfully launching Trodelvy, the first TROP-2 directed antibody-drug conjugate for the treatment of triple-negative breast cancer. Immunomedics was acquired by Gilead Sciences for $21B in September 2020. Previously, he served as Vice President of U.S. Hematology-Oncology at Celgene Corporation. Prior to joining Celgene, he held various commercial roles at both Novartis Oncology and Genentech, where he led several successful product launches for blockbuster brands. Mr. Delaney also serves on the Board of Directors of MJH Life Sciences, one of the leading medical-media companies in the United States. He received an MBA from the Stern School of Business at the New York University and a B.A. in biology from Rutgers University.
高管简历
中英对照 | 中文 | 英文- 黄岚
黄岚博士在中国和美国的生物技术产业拥有十多年的创业经验。她发明并拥有多项生物技术产品专利，用于肿瘤和皮肤病适应症。2009年，她成为“国家千人计划”的获得者之一。在2013年创立BeyondSpring之前，黄岚博士共同创办了无锡麦涛岚华生物科技有限公司，并于2010年将其自主设计的多肽药物的中国权利卖给中国制药公司排名前三的上药集团。在中国她还共同创立了一个临床CRO公司Paramax，之后出售给RPS （一个全球性CRO），后者在2011年以超过2亿美元将之出售给Warburg Pincus。此外，黄博士还是Forward Venture公司的合伙人，负责Forward Venture的投资公司和中国制药公司的合作计划。黄岚博士曾在Memorial Sloan-Kettering癌症中心（MSKCC）学习，其博士学位由加州大学伯克利分校化学系授予，同时也获得了北美优秀女博士毕业奖。她的关于Ras和P53的癌症信号通路的研究发表在Science and Nature杂志上。黄岚博士曾就读于上海复旦大学，且获得了劳伦斯大学的学士学位、优等生和美国大学优生等荣誉，目前她在那里担任董事。
Lan Huang,is co-founder, Chairperson and Chief Executive Officer and has been a member of board of directors since November 2014. Dr. Huang has over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang co-founded Wanchun Biotech, the former holding company of U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd, where she served as Chief Executive Officer in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd, were sold to Shanghai Pharmaceutical Group in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Currently, Dr. Huang serves on the board of directors of Sincere Efforts Foundations Inc., a non-profit organization. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving P53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications. Dr. Huang received her B.A., magna cum laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women's Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.- 黄岚博士在中国和美国的生物技术产业拥有十多年的创业经验。她发明并拥有多项生物技术产品专利，用于肿瘤和皮肤病适应症。2009年，她成为“国家千人计划”的获得者之一。在2013年创立BeyondSpring之前，黄岚博士共同创办了无锡麦涛岚华生物科技有限公司，并于2010年将其自主设计的多肽药物的中国权利卖给中国制药公司排名前三的上药集团。在中国她还共同创立了一个临床CRO公司Paramax，之后出售给RPS （一个全球性CRO），后者在2011年以超过2亿美元将之出售给Warburg Pincus。此外，黄博士还是Forward Venture公司的合伙人，负责Forward Venture的投资公司和中国制药公司的合作计划。黄岚博士曾在Memorial Sloan-Kettering癌症中心（MSKCC）学习，其博士学位由加州大学伯克利分校化学系授予，同时也获得了北美优秀女博士毕业奖。她的关于Ras和P53的癌症信号通路的研究发表在Science and Nature杂志上。黄岚博士曾就读于上海复旦大学，且获得了劳伦斯大学的学士学位、优等生和美国大学优生等荣誉，目前她在那里担任董事。
- Lan Huang,is co-founder, Chairperson and Chief Executive Officer and has been a member of board of directors since November 2014. Dr. Huang has over 15 years of entrepreneurial experience in the Chinese and U.S. biotechnology industries. In 2010, Dr. Huang co-founded Wanchun Biotech, the former holding company of U.S. subsidiary. In 2007, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd, where she served as Chief Executive Officer in 2010 and continues to hold a directorship. The rights related to the development and marketing of the peptide drug in China, which drug Dr. Huang designed while at Wuxi MTLH Biotechnology Co. Ltd, were sold to Shanghai Pharmaceutical Group in 2010. Additionally, in 2008, Dr. Huang co-founded Paramax International Inc., a CRO that conducts clinical trials for global biopharmaceutical and medical device companies. Paramax International Inc. was acquired by ReSearch Pharmaceutical Services, Inc. in 2009. Currently, Dr. Huang serves on the board of directors of Sincere Efforts Foundations Inc., a non-profit organization. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her research in cancer signaling pathways involving P53 degradation was published in Science. Her translational research in cancer signaling pathways involving RAS was published in two Nature papers. She has invented and holds patents for a number of biotech products for oncology and dermatology indications. Dr. Huang received her B.A., magna cum laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She received her Ph.D. in chemistry from the University of California at Berkeley, where she won the international-level Women's Opportunity Award given by Soroptimist International. She also studied at Fudan University in Shanghai, China.
- June Lu
June Lu，她曾担任Transitional Medicine执行董事。Lu博士在创新药研发方面拥有近25年的行业经验，是一位在管线项目和管线资产的科学、转化和战略分析方面卓有成就的专业人士。她的特殊专长是在生物技术和制药行业的多学科协作领导经验。在BeyondSpring之前，Lu博士曾在开发177Lu-PSMA-617的Endocyte工作，Endocyte现已批准药物Pluvicto，并出席了诺华旗下公司Advanced Accelerator Applications和诺华生物医学研究所。Lu博士带领跨职能项目团队开发了针对癌症（folateImmune；双特异性CAR-T细胞疗法）和自身免疫（如DHFR/mTOR抑制剂）的基于小分子的策略。此外，Lu博士还在巨噬细胞靶向、耐药性&与PD-1/CTLA-4抑制剂等IO药物的组合、靶点识别/预验证和适应症选择等方面带头进行了深入的科学努力。Lu博士撰写了约30多篇同行评审出版物，是多项专利的发明人。普渡大学化学（生物化学科）博士、浙江工业大学分析化学学士。
June Lu,served as Executive Director of Transitional Medicine. Dr. Lu has nearly 25 years of industry experience in innovative drug research and development and is an accomplished professional in scientific, translational and strategic analysis aspects of pipeline projects and pipeline assets. Her special expertise is in multidisciplinary, collaborative leadership experiences in the biotech and pharmaceutical industry. Prior to BeyondSpring, Dr. Lu worked at Endocyte, which developed 177Lu-PSMA-617, now approved drug Pluvicto, and at Advanced Accelerator Applications, a Novartis company, and Novartis Institute for Biomedical Research. Dr. Lu has led cross-functional project teams to develop small molecule-based strategies for cancer (FolateImmune; bispecific CAR-T cell therapy) and autoimmunity (such as DHFR/mTOR inhibitors). In addition, Dr. Lu has spearheaded deep-dive scientific efforts in macrophage-targeting, drug resistance & combinations with IO agents such as PD-1/CTLA-4 inhibitors, target identification/pre-validation and indication selections. Dr. Lu has authored about 30+ peer-reviewed publications and is an inventor for multiple patents. She received her Ph.D. in chemistry (biochemistry division) from Purdue University and B.S. degree in analytical chemistry from Zhejiang University of Technology.- June Lu，她曾担任Transitional Medicine执行董事。Lu博士在创新药研发方面拥有近25年的行业经验，是一位在管线项目和管线资产的科学、转化和战略分析方面卓有成就的专业人士。她的特殊专长是在生物技术和制药行业的多学科协作领导经验。在BeyondSpring之前，Lu博士曾在开发177Lu-PSMA-617的Endocyte工作，Endocyte现已批准药物Pluvicto，并出席了诺华旗下公司Advanced Accelerator Applications和诺华生物医学研究所。Lu博士带领跨职能项目团队开发了针对癌症（folateImmune；双特异性CAR-T细胞疗法）和自身免疫（如DHFR/mTOR抑制剂）的基于小分子的策略。此外，Lu博士还在巨噬细胞靶向、耐药性&与PD-1/CTLA-4抑制剂等IO药物的组合、靶点识别/预验证和适应症选择等方面带头进行了深入的科学努力。Lu博士撰写了约30多篇同行评审出版物，是多项专利的发明人。普渡大学化学（生物化学科）博士、浙江工业大学分析化学学士。
- June Lu,served as Executive Director of Transitional Medicine. Dr. Lu has nearly 25 years of industry experience in innovative drug research and development and is an accomplished professional in scientific, translational and strategic analysis aspects of pipeline projects and pipeline assets. Her special expertise is in multidisciplinary, collaborative leadership experiences in the biotech and pharmaceutical industry. Prior to BeyondSpring, Dr. Lu worked at Endocyte, which developed 177Lu-PSMA-617, now approved drug Pluvicto, and at Advanced Accelerator Applications, a Novartis company, and Novartis Institute for Biomedical Research. Dr. Lu has led cross-functional project teams to develop small molecule-based strategies for cancer (FolateImmune; bispecific CAR-T cell therapy) and autoimmunity (such as DHFR/mTOR inhibitors). In addition, Dr. Lu has spearheaded deep-dive scientific efforts in macrophage-targeting, drug resistance & combinations with IO agents such as PD-1/CTLA-4 inhibitors, target identification/pre-validation and indication selections. Dr. Lu has authored about 30+ peer-reviewed publications and is an inventor for multiple patents. She received her Ph.D. in chemistry (biochemistry division) from Purdue University and B.S. degree in analytical chemistry from Zhejiang University of Technology.